PARKINSON'S DISEASE NEWS
Parkinson's Disease News covers all significant new research, reports, books, and resources concerning Parkinson's Disease. Articles are chosen on the basis of their medical significance or potential interest. Our overwhelming priority is the facts, regardless of whether they contradict prevailing views or vested interests. Analysis and further information are provided either to explain the background or implications, or to balance misleading claims. If you notice errors or inadequacies, or dispute what is written, or want to propose articles, please e-mail firstname.lastname@example.org.
29th July 2014 - New research
DISCOVERY OF NEW PARKINSON'S DISEASE GENETIC FACTORS
Nature Genetics  (27 July) (M.A.Nalls, N.Pankratz, C.M.Lill,
C.B.Do, D.G. Hernandez, M.Saad, A.L.De Stefano, E.Kara, J.Bras, M.Sharma,
C.Schulte, M.F.Keller, S.Arepalli, C.Letson, C.Edsall, H.Stefansson, X.Liu,
H.Pliner, J.H.Lee, R.Cheng, et al)
They conducted an extensive analysis of Parkinson's Disease genetic studies. Twenty six sites were identified as having a significant genetic association with Parkinson's Disease. These and six additional sites that had previously not been reported were then tested. In total, they identified and replicated 28 independent risk variants for Parkinson's disease across 24 loci (positions on the gene). Although the effect of each individual genetic risk was found to be small, a risk profile analysis showed that there was a substantial cumulative risk of developing Parkinson's Disease because of them. The risk was actually tripled when several genetic risk factors occurred simultaneously.
Their results suggested that the more variants a person has the greater the risk, which is up to three times higher for developing Parkinson's Disease in some cases. Genetic causes of Parkinson's Disease usually make Parkinson's Disease more likely rather than inevitable. Although genetic causes of Parkinson's Disease are uncommon the actual prevalence is unknown. In order to refer to this article on its own click here
27th July 2014 - New research
NASAL DELIVERY OF PARKINSON'S DISEASE TREATMENT
The percentage accuracy observed for intra-day and inter-day batch samples was very high. Bromocriptine was found to be stable in all exposed conditions. Bromocriptine nanoparticles also showed greater retention into the nostrils for about four hours. Direct bromocriptine nanoparticle nose-to-brain transport was shown to then bypass the blood-brain barrier. Most importantly, bromocriptine nanoparticles administered nasally showed significantly high dopamine concentrations.
The researchers concluded that Nanoparticle drug delivery system could be potentially used as a nose-to-brain drug delivery carrier for improving the existing means of treating Parkinson's Disease. In order to refer to this article on its own click here
E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new articlesss are added to Parkinson's Disease News, please merely e-mail email@example.com with the message "subscribe". No form of identity is required. E-mail addresses are not used for any other purpose.
23rd July 2014 - News release
APOMORPHINE CLINICAL TRIAL FOR PARKINSON'S DISEASE
CTH-105 is a Phase 2 clinical study of APL-130277. APL-130277 will be studied in 16 people with Parkinson's disease who have not used apomorphine and who experience at least one daily "off" episode, with a total duration of "off" in any 24-hour period of at least 2 hours. This open study will examine the effect of APL-130277 on relieving "off" episodes over a single day, with dose-titration used to determine dose strengths necessary for future clinical use.
In particular, the dose strength information is necessary in order to conduct the larger CTH-300a efficacy study in apomorphine naive patients, which is expected to commence at the end of 2014. The primary means of assessment will be the change in the UPDRS III score, which is the most widely used Parkinson's Disease symptom questionnaire. For more information go to Cynapsus In order to refer to this article on its own click here
17th July 2014 - New research
SOCIAL PHOBIAS ARE COMMON IN PARKINSON'S DISEASE
14th July 2014 - New research
MISDIAGNOSIS OF PARKINSON'S DISEASE
Researchers aimed to determine the diagnostic accuracy of a clinical
diagnosis of Parkinson's Disease using neuropathologic diagnosis as the
standard. The accuracy of diagnosis was found to be very poor.
neuropathologic findings of Parkinson's Disease as the standard, this study
established a finding of only 26% accuracy for a clinical diagnosis of
Parkinson's Disease in untreated patients, 53% accuracy in early Parkinson's
Disease of less than five years duration that was responsive to medication,
and 85% diagnostic accuracy in Parkinson's Disease of longer duration that
was medication-responsive. Clinical variables that improved diagnostic
accuracy were medication response, motor fluctuations, dyskinesias, and
hyposmia (reduced sense of smell).ic accuracy in Parkinson's Disease of
longer duration that was medication-responsive.
This study showed that a clinical diagnosis of Parkinson's Disease identifies people who will have pathologically confirmed Parkinson's Disease with a sensitivity of 88% and specificity of 68%. For more information concerning the diagnosis of Parkinson's Disease go to Diagnosis of Parkinson's Disease In order to refer to this article on its own click here
10th July 2014 - New research
Ŗ-ASARONE INCREASES L-DOPA IN PARKINSON'S DISEASE
In order to increase the effect of L-dopa it is usually administered in combination with a dopa decarboxylase inhibitor. In Sinemet, L-dopa is combined with carbidopa. In Madopar, L-dopa is combined with benserazide. The co-administration of Ŗ-asarone and Levodopa is being developed as a means of improving the effect of L-dopa even further.
Ŗ-asarone is found in the flowering plant acorus and also in asarum, which is known as wild ginger. For more information go to Ansarone
In animal studies the use of L-dopa in combination with Ŗ-asarone was
compared to the use of existing methods of treating Parkinson's Disease.
Dopamine levels were found to increase in the brain (in the striatum) and in
blood plasma in response to Ŗ-asarone. The co-administration of Ŗ-asarone
and L-dopa could also increase the levels in blood plasma of tyrosine
hydroxylase, which is the enzyme responsible for the formation of L-dopa.
Altogether, Ŗ-asarone was found to have an effect on converting L-dopa into
dopamine by modulating the activity of dopamine metabolism.
The mechanism of co-administration of Ŗ-asarone and L-dopa is different from that of Sinemet and Madopar in the treatment of Parkinson's Disease. The co-administration of Ŗ-asarone and L-dopa may be more beneficial to Parkinson's Disease treatment than the existing methods and so could eventually replace them. In order to refer to this article on its own click here
5th July 2014 - New research
THE WORLDWIDE PREVALENCE OF PARKINSON'S DISEASE
Researchers sought to synthesize studies on the prevalence of Parkinson's Disease to obtain an overall view of how the prevalence varies by age, gender, and geographic location. Geographic location was stratified by the following groups : Asia, Africa, South America, Europe / North America / Australia. Data were analyzed by age group, geographic location, and gender.
of worldwide data showed a rising prevalence of Parkinson's Disease with
age, with (per 100,000) : 41 in 40 to 49 year olds, 107 in 50 to 59 year
olds, 173 in 55 to 64 year olds, 428 in 60 to 69 year olds, 1087 in 70 to 79
year olds, and 1903 in those aged older than 80.A
significant difference was seen in prevalence geographically only for people
who were 70 to 79 years old, with a prevalence of 1601 (per 100,000) in
people in North America, Europe, and Australia, compared to only 646 (per
100,000) in people from Asia. Differences in prevalence according to gender
was found only for people who were 50 to 59 years old, with a prevalence of
41 in females and 134 in males.
29th June 2014 - New research
COMPARISON OF L-DOPA, AGONISTS AND MAO INHIBITORS
Whether the initial treatment for Parkinson's disease should consist of L-dopa, dopamine agonists, or MAO B inhibitors is uncertain. So researchers aimed to establish which of these three classes of drug, as initial treatment, provided the most effective long-term control of symptoms and best quality of life for people with early Parkinson's Disease.
newly diagnosed with Parkinson's disease were randomly assigned between the
use of L-dopa, dopamine agonists and MAO B inhibitors. After three years
PDQ-39 mobility scores averaged 1∑8 points better in people assigned to
L-dopa. PDQ-39 mobility scores were 1∑4 points better in people assigned to
MAO B inhibitors when compared to those taking dopamine agonists. L-dopa was
not significantly advantageous for EQ-5D utility scores, dementia,
admissions to institutions, and death rates. Treatments were discontinued in
28% of those taking dopamine agonists, 23% of those taking MAOB inhibitors,
but only 2% of those taking L-dopa.
21st June 2014 - New research
CIRCADIAN RHYTHMS IN PARKINSONS' DISEASE
People with Parkinson's Disease have been found to have blunted circadian rhythms. Circadian rhythms are the alterations of endocrine functions that take place in a regulated manner over a roughly 24 hour period. The pineal gland produces melatonin, which is a hormone that regulates the circadian rhythms. For more information go to Circadian rhythms
differences and the range of secretion of melatonin from the pineal gland
were found to be lower in Parkinson's Disease than in people that do not
have Parkinson's Disease. Overall Parkinson's Disease symptoms and duration
of symptoms were not significantly related to the circadian rhythm. So it
was only daytime sleepiness and not Parkinson's Disease symptoms generally
that are affected by the blunted circadian rhythm that can occur in
Parkinson's Disease. Dopamine regulates melatonin
secretion. Therefore, the reduced dopamine that occurs in Parkinson's
Disease will lead to an altered circadian rhythm.
9th June 2014 - New research
FAHR'S SYNDROME IS A CAUSE OF PARKINSON'S DISEASE
Journal of the College of Physicians and Surgeons - Pakistan  24 (5) : S104-S106 (N.Dildar, H.Akram, I.M.Qasmi, M.N.Qureshi, S.Khan) Complete abstract
Fahr's Syndrome is a rare inherited neurological disorder that can present with a wide spectrum of symptoms, including those of Parkinson's Disease. It is characterised by abnormal deposits of calcium in areas of the brain that control movement, including the basal ganglia and the cerebral cortex. For more information go to Fahr's Syndrome
Symptoms of Fahr's Syndrome that are similar to those of Parkinson's Disease may include deterioration of motor function, dementia, dysarthria (poorly articulated speech), tremors, muscle rigidity, a mask-like facial appearance, shuffling gait, and a "pill-rolling" motion of the fingers. These symptoms generally occur later in the development of the disease.
More common symptoms of Fahr's Syndrome include dystonia (disordered muscle tone) and chorea (involuntary, rapid, jerky movements). The age of onset of Fahr's Syndrome is typically in the 40s or 50s, which is similar to Parkinson's Disease, although it can also occur at any time in childhood or adolescence.
Due to the possible similarity of symptoms to those of Parkinson's Disease, Fahr's Syndrome should be considered as an important differential diagnosis in cases of Parkinsonism. In order to refer to this article on its own click here
20th May 2014 - New research
PRAMIPEXOLE CLINICAL TRIAL RESULTS IN PARKINSON'S DISEASE
European Journal of Neurology  21 (5) : 736-743 (R.A.Hauser, A.H.Schapira, P. Barone, Y.Mizuno, O.Rascol, M.Busse, C.Debieuvre, M.Fraessdorf, W.Poewe) Complete abstract
The long term safety and efficacy of pramipexole was assessed as an extended-release oral formulation and immediate release formulation in early or advanced Parkinson's Disease. Pramipexole, which is marketed as Mirapex, Mirapexin, and Sifrol, is a dopamine agonist. For more information go to Pramipexole
In those people with early Parkinson's Disease the reported side effects were somnolence (15%), peripheral edema (11%) and back pain (10%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 6.6 when using extended release pramipexole and 6.3 when using immediate release pramipexole. In those people with advanced Parkinson's Disease the reported side effects were dyskinesia (27%), somnolence (13%), and impulse control disorders (1%). The scores on the Parkinson's Disease symptom score (UPDRS) after over 2 years were down by 11.5 when using extended release pramipexole and 9.1 when using immediate release pramipexole.
In both early and advanced Parkinson's Disease better efficacy was achieved when using the extended release version of pramipexole. The adverse events were typical for dopaminergic drugs. In order to refer to this article on its own click here
16th May 2014 - New research
THE EFFECT OF ACUPUNCTURE IN PARKINSON'S DISEASE
Journal of Neurological Science  Apr 24 [Epub ahead of print] (H.J.Kim, B.S.Jeon) Complete abstract
A comprehensive review was carried out to assess the evidence from recent clinical studies regarding the efficacy of acupuncture on Parkinson's Disease. Acupuncture is an ancient Chinese form of medicine in which fine needles are inserted and manipulated into the skin at certain points on the body for therapeutic purposes. For more information go to Acupuncture
Eleven suitable studies were indentified. Two randomized clinical trials failed to show any benefit. The other study did not show beneficial effects of needle acupuncture. Three randomized clinical trials that assessed effects of acupuncture in addition to conventional drugs reported beneficial effects of acupuncture. However, there was no control acupuncture group in those studies. Two uncontrolled studies showed significant positive effects of acupuncture, while other two uncontrolled clinical trials failed. Safety and tolerability were reported only in five clinical trials. No studies evaluated the long lasting effects of acupuncture following cessation of the treatment.
The number of clinical trials, their total sample size, and the way they were carried out, were not enough to prove the favorable effects of acupuncture. So far the evidence for the effectiveness of acupuncture for treating Parkinson's Disease is not convincing. In order to refer to this article on its own click here
9th May 2014 - New research
DIABETES TREATMENT FOR PARKINSON'S DISEASE
Journal of Parkinson's Disease  Mar 24 [Epub ahead of print] (I.Aviles-Olmos, J.Dickson, Z.Kefalopoulou, A.Djamshidian, J.Kahan, P.E.Fmedsci, P.Whitton, R.Wyse, T. Isaacs, A.Lees, P.Limousin, T.Foltynie) Complete abstract
Exenatide, which is a treatment for diabetes, has been tested as a disease modifying treatment for Parkinson's Disease. Exenatide is an injected glucagon-like peptide-1 agonist medication marketed as Byett and Bydureon. It is used in the treatment of insulin resistance in patients with Type 2 diabetes. It differs in pharmacological action and chemical structure from insulin. For more information go to Exenatide
Using the MDS-UPDRS, which is a means of assessing the extent of Parkinson's Disease symptoms, people with Parkinson's Disease were assessed who had previously taken Exenatide. People with Parkinson's Disease had an advantage of 5.6 points (with a range of 2.2 to 9.0) on the assessment. They also had a better score when assessed concerning dementia. Unusually, the effect of Exenatide on Parkinson's Disease had continued beyond its use. The authors do not suggest how this diabetes drug can have effect in Parkinson's Disease.
In a previous study, when people with moderate Parkinson's Disease received subcutaneous injections of Exenatide for a year there were marginal improvements in Parkinson's Disease motor and cognitive measures. Exenatide treated patients had a mean improvement after one year on the UPDRS of 2.7 compared with a mean decline of 2.2 points in controls. Exenatide was well tolerated but weight loss was common. For more information go to the Complete abstract In order to refer to this article on its own click here
30th April 2014 - New book
ALTER YOUR COURSE : PARKINSON'S - THE EARLY YEARS
Monique L.Giroux, Sierra M.Farris
Publisher's description : This book is not intended to be filled with facts about the disease; there are many books that cover these topics. Instead we have focused on 2 questions, ďDoes PD present an opportunity in disguise ? What information, actions or attitudes are most helpful early in the disease to set the stage for living your best now and into the future?Ē Alter Your Course tells a different story -one that is emerging within you -the person with PD. Your story can be filled with hope, inspiration, empowerment, resiliency and strength. Each chapter concludes with helpful advice designed to help you take control of your PD journey and alter your course. The last chapter is filled with advice; from people like you-living with PD. Click here for more details For more books concerning Parkinson's Disease go to go Parkinson's Disease books
24th April 2014 - New research
CLINICAL TRIAL OF GENE THERAPY FOR PARKINSON'S DISEASE
Lancet  383 (9923) : 1138-1146 (S.Palfi, J.M.Gurruchaga, G.S.Ralph, H.Lepetit, S.Lavisse, P.C.Buttery, C. Watts, J.Miskin, M.Kelleher, S.Deeley, et al) Complete abstract
ProSavin (NLX-P101) uses LentiVector gene delivery technology to deliver genes for three enzymes they suggest are required for the formation of dopamine. The product is administered locally to the relevant region of the brain in order to increase the brain's own capacity for the formation of dopamine. For more information go to Prosavin
In a clinical trial of Prosavin, 15 patients received ProSavin, with three people taking a low dose, six taking a mid dose, and six taking a high dose. During the first 12 months 54 drug-related adverse events were reported (51 mild and 3 moderate). The most reported were increased dyskinesias, and on-off phenomena. No serious adverse events related to the drug or the surgical procedure were reported. A moderate improvement in mean Parkinson's Disease symptom scores was recorded in all patients tested at 6 months and 12 months.
In a previous clinical trial the degree of efficacy was quite moderate, with an average 27% improvement after 3 months, peaking at 31% after 6 months, and declining to 23% after 2 years. In the long term stimulating gene and enzyme levels artificially reduces a person's own formation of those genes and enzymes. In order to refer to this article on its own click here
15th April 2014 - New research
GOOGLE GLASS BEING TESTED FOR PARKINSON'S DISEASE
Newcastle University are investigating Google Glass as an assistive aid in order to help people with Parkinson's Disease retain their independence for longer.
Glass is a wearable computer being developed by Google. At first glance Glass appears to be no more than a pair of designer glasses. However, the system works like a hands-free smartphone that displays visual information on the lens of the Glass.
The technology is voice-operated and is also linked to the internet. It is not currently available outside the USA. For more information go to a review of Google Glass
Researchers have been working with a group of Parkinson's Disease volunteers aged between 46-70 years. They are working on the next stage of the project, using the technology to provide discreet prompts linked to key behaviours typical of Parkinson's Disease, such as reminding the individual to speak up or to swallow to prevent drooling. Glass can also be used as a personal reminder for things such as taking medication and making appointments. Glass is connected to the internet so that the wearer can link it to computers and mobile phones. So if the wearer is alone they just have to look through the Glass so that carers or relatives will be able to see exactly where they are. The wearer can also tell it to call someone and it rings them. For more information go to Newcastle University In order to refer to this article on its own click here
7th April 2014 - New research
THE NAZI DISCOVERER OF L-DOPA FOR PARKINSON'S DISEASE
Journal of the History of the Neurosciences 2014 Apr 3 [Epub ahead of print]
(H.Czech, L.A. Zeidman)
Researchers have determined that Birkmayer was not only an early illegal member of the SS and the Nazi party but also took part in "de-Jewification". He also was a leader in the Nazi racial policy office and was praised for his dedication and fanaticism despite being forced to later resign from the SS. He sought support from leading Viennese Nazis and was able to maintain his professional status for the war's remainder. Postwar, he succeeded at reintegration personally and professionally into Austrian society, all but erasing any obvious ties to his Nazi past.
In 1960 Dr. Hornykiewicz demonstrated that dopamine levels were below normal in the brains of people who died of Parkinson's Disease. He and Dr. Arvid Carlsson, believed that L-dopa, a precursor in the biosynthesis of dopamine, could treat Parkinson's Disease. Dr. Hornykiewicz and Dr. Birkmayer began to treat patients with L-dopa. They noticed marked short-term improvements. They published their findings in 1961, which eventually led to L-dopa being the most widely used treatment for Parkinson's Disease. For more information go to Walther Birkmayer In order to refer to this article on its own click here
2nd April 2014 - New clinical trial
ISRADIPINE BEING TESTED FOR PARKINSON'S DISEASE
Isradipine is a calcium channel blocker that is marketed as Dynacirc. Dynacirc is a drug that is prescribed to treat high blood pressure. For more information concerning Dynacirc go to Medline Plus
The basis for the clinical trial is that data from large studies found that there was a lower incidence of Parkinson's Disease among those people who took Isradipine.
However, when Isradipine was tested in Phase II clinical trials in people who had Parkinson's Disease Isradipine caused side effects. The most common adverse events were peripheral edema and dizziness. Isradipine also failed to have any significant effect on Parkinson's Disease symptoms. For more information go to the Phase II clinical trial
In order to effectively treat Parkinson's Disease effectively dopamine formation must be increased but, even in theory, calcium channel blockers can not do that. In order to refer to this article on its own click here
28th March 2014 - New research
COENZYME Q10 HAS NO EFFECT IN PARKINSON'S DISEASE
Coenzyme Q10, an antioxidant that has been widely used for Parkinson's Disease has been found to have no significant effect. Coenzyme Q10 (CoQ10) is a supplement, which supports mitochondrial function in the neurons, and has been claimed to slow the progression of Parkinson's Disease. For more information go to Medline Plus
People with Parkinson's Disease were given either a placebo, 1200mg of CoQ10 per day, or 2400mg of CoQ10 per day. All of them were also given 1200 IU per day of vitamin E. Participants were observed for 16 months or until a disability requiring dopaminergic treatment. The treatments were well tolerated with no safety concerns. However, the worsening of Parkinson's Disease was actually related to the higher Coenzyme Q10 dose. Those taking no Coenzyme Q10 worsened by 6.9 points on the UPDRS. Those taking 1200mg worsened by 7.5 points. Those taking 2400mg worsened by 8.0 points. So Coenzyme Q10 was not only not beneficial it appeared, if anything, to be detrimental.
In previous studies Coenzyme Q10 was found to be ineffective in Parkinson's Disease in daily doses of 200mg, 300mg, 400mg, 600mg, and 800mg. Only one Coenzyme Q10 study has ever shown any improvement in Parkinson's Disease, using 360mg, but the effects were mild and were only assessed for four weeks. Daily doses of 300mg, 600mg and 1200 mg failed to improve the symptoms of Parkinson's Disease but reduced the rate of deterioration. In order to refer to this article on its own click here
23rd March 2014 - New research
PARKINSON'S DISEASE INCREASES THE RISK OF INJURIES
People with Parkinson's Disease have been found to increase their likelihood of most accidental injuries, especially head injuries. The risk of injury increases with age.
People with Parkinson's Disease were found to have the following increased likelihood of injuries times what is normal : head injury 1.9, bone fracture and dislocation 1.4, all injuries 1.3, injury to spinal cord, plexus and nerves 1.25, superficial injuries and contusions 1.20, burns 1.0.
The injury risk for those people with Parkinson's Disease who were 69-79 years old was significantly higher than those who were 50-69 years old.
So people with Parkinson's Disease demonstrate a significantly elevated risk of developing all accidental injury types except injuries caused by burns. The risk of injury increases as age increases. In previous studies Coenzyme Q10 was found to be ineffective in Parkinson's Disease in daily doses of 200mg, 300mg, 400mg, 600mg, and 800mg. Only one Coenzyme Q10 study has ever shown any improvement in Parkinson's Disease, using 360mg, but the effects were mild and were only assessed for four weeks. Daily doses of 300mg, 600mg and 1200 mg failed to improve the symptoms of Parkinson's Disease but reduced the rate of deterioration. In order to refer to this article on its own click here.
22nd March 2014 - New research
THE EFFECT OF AGE OF ONSET ON PARKINSON'S DISEASE
The clinical features and development of Parkinson's Disease has been found to differ in many respects according to the age of onset of Parkinson's Disease.
The age of onset can be roughly divided in to young onset (49 years old or younger), middle onset (50 to 69 years old), and late onset (70 years old or later). Data collected included age at symptom onset, year of onset, family history of Parkinson's disease in first and second degree relatives, predominant first symptom, first anti parkinsonian medication prescribed, frequency of L-dopa-induced dyskinesia, therapy related dystonia, therapy related gastrointestinal side effects, hallucinations, dementia, depression and apathy. In numbers, the middle onset was the largest group (51%), followed by those with late onset (39%) and then those with young onset (10%).
Those with young onset were found to have a more frequent family history of Parkinson's disease and longer survival. Symptoms other than tremor were more frequent as the initial symptom of the young onset group. Depression was more frequent in the young onset group than middle onset or old onset. The frequency of tremor as the first symptom increased with advancing age at onset. The frequency of treatment related dyskinesia or dystonia decreased with advancing age at onset. In order to refer to this article on its own click here.
10th March 2014 - New research
MAGNETIC RESONANCE IMAGING ACCURATELY DIAGNOSES PARKINSON'S DISEASE
Parkinson's Disease has been diagnosed with almost complete accuracy using a scanning method called Magnetic Resonance Imaging (MRI).
Magnetic resonance imaging (MRI) is a type of scan that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body. An MRI scanner is a large tube that contains powerful magnets. The patient lays inside the tube during the scan and is moved into the scanner either head or feet first. The MRI scanner is operated by a radiographer who controls the scanner using a computer. For more information go to Magnetic Resonance Imaging
An evaluation was carried out of the substantia nigra (SN) of people who did and who did not have Parkinson's Disease. The substantia nigra (SN) is the area of the brain most affected by Parkinson's Disease. Deviations from the normal appearance of the substantia nigra were described and indicated as abnormal. The abnormal architecture of the substantia nigra allowed a discrimination between people who did and who did not have Parkinson's Disease with a sensitivity and specificity of 100% and 96% respectively. In order to refer to this article on its own click here.
5th March 2014 - New research
L-DOPA'S EFFECT ON NON-MOTOR SYMPTOMS OF PARKINSON'S DISEASE
People with Parkinson's Disease have the characteristic motor symptoms of Parkinson's Disease but also have a wide range of non-motor symptoms. Although L-dopa is a widely used basis for treating Parkinson's Disease, L-dopa (with carbidopa) has been found to have little effect on many of the non-motor symptoms of Parkinson's Disease.
When assessed, the most frequent non-motor symptoms of Parkinson's Disease were fatigue 56%, excessive sweating 54%, insomnia 54%, akathisia (restlessness) 47%, anxiety 45%, and constipation 17%. However, after five months of taking L-dopa and carbidopa, frequencies of most of the non-motor symptoms decreased only slightly, showing that there was little significant effect of L-dopa and carbidopa.
Some non-motor symptoms of Parkinson's Disease are not improved by taking L-dopa because they are due to the side effects of Parkinson's Disease drugs. Some non-motor symptoms of Parkinson's Disease are not improved much by taking L-dopa because they are due to a combination of Parkinson's Disease and other factors that are not related to the dopamine deficiency that occurs in Parkinson's Disease. In order to refer to this article on its own click here.
4th March 2014 - New research
THE EFFECT OF MILD BRAIN INJURY ON PARKINSON'S DISEASE
Researchers assessed all of the studies concerning the risk of Parkinson's Disease after mild traumatic brain injury. Sixty-five studies were eligible and reviewed, but only five of these with a low risk of bias were accepted as scientifically admissible.
One of the five studies showed a significant association between Mild traumatic brain injury and Parkinson's Disease. It was found to be 1.5 times more likely. However, the likelihood decreased when the time between the injury and Parkinson's Disease diagnosis was greater. The other four studies did not find any association. So the available evidence argues against a causal association between Mild traumatic brain injury and Parkinson's Disease. Although Parkinson's Disease is often claimed to be due to the loss or damage of the cells involved in Parkinson's Disease not a single study has ever shown this to be true. In order to refer to this article on its own click here.
28th February 2014 - New research
CIRCADIAN RHYTHMS IN PARKINSON'S DISEASE
Diurnal fluctuations of Parkinson's Disease symptoms and a high prevalence
of sleep-wake disturbances in Parkinson Disease suggest that the circadian
rhythm is affecting these symptoms. The circadian rhythm is a roughly 24
hour cycle that regulates physiological processes by various factors such as
daylight. Secretion of melatonin from the pineal gland is largely
responsible for this regulation. For more information go to
27th February 2014 - History
EARTHWORMS AND OIL OF WINGED ANTS FOR PARKINSON'S DISEASE
Nicholas Culpeper (1616-1654) was an English botanist, herbalist, physician and astrologer. He published books, The English Physitian (1652) and the Complete Herbal (1653). The Complete Herbal contains both pharmaceutical and herbal knowledge. Among the recommendations in Complete Herbal, he suggests sage for "sinews, troubled with palsy and cramp". For centuries prior to this, Sage had also been recommended for tremor in the hands. Amongst other plant remedies Culpepper suggested for palsy and trembling were bilberries, briony (called "English mandrake"), and mistletoe. In the 1696 edition of his Pharmacopoeia Londinensis, a variety of substances were claimed to be useful in the treatment of "palsies", the "dead palsy", and "tremblings". These included "oil of winged ants" and preparations including earthworms. For more concerning the history of Parkinson's Disease go to the History of Parkinson's Disease.
12th February 2014 - New research
HEARING LOSS IN PARKINSON'S DISEASE
Hearing loss has been found to be three times more likely in elderly people who have Parkinson's Disease. This is partly due to the increased prevalence of loss of hearing with age. However, hearing loss is still 1.77 times more likely in elderly people with Parkinson's Disease than it is in elderly people who do not have Parkinson's Disease.
Hearing is perceived in the Cochlea, in the Organ of Corti, which is the sensory organ of hearing. For more information go to Cochlea. Dopamine, whose deficiency causes Parkinson's Disease, helps to protect against noise exposure in the Cochlea    . Insufficient dopamine can therefore lead to damage that can result in loss of hearing. The cause of the increased likelihood of loss of hearing that can occur in Parkinson's Disease is therefore originally probably biochemical rather than structural. In order to refer to this article on its own click here.
11th February 2014 - New book
PIONEERS OF RECOVERY : HOW PEOPLE WITH PARKINSON'S DISEASE REVERSE THEIR SYMPTOMS
Publisher's description : Parkinsons Recovery Radio show guests often talk about how they reversed the symptoms of Parkinsons Disease. Now you can read nine of these amazing stories as they were first told on the radio show in this 2012 release of Pioneers of Recovery. Each chapter includes details on the steps that each pioneer took to make miracle of healing happen. Therapies that paved the road to recovery include : TMJ adjustments, Candida cleanses, Voice Profiling, sound therapy, Tai Chi, Martial Arts, Qigong, Low Dose Naltrexone, forced exercise, Chinese medicine, supplements, diet, detoxes. You will be intrigued by how each pioneer went about reversing their symptoms Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
8th February 2014 - New review
SKIN DISORDERS IN PARKINSON'S DISEASE
The integumentary system is the
skin and its associated glands, including the sweat glands, the sebaceous
glands, and the
hair and nails. Those medical disorders asociated with the skin that
commonly occur in Parkinson's Disease are seborrhea, hyperhidrosis, and
23rd January 2014 - New review
IN PARKINSON'S DISEASE
Due to the reduced respiratory capacity, people with Parkinson's Disease are more prone to the effects of pneumonia, which occurs more commonly than expected in Parkinson's Disease, but not because of Parkinson's Disease . Consequently, pneumonia is the most common cause of death associated with Parkinson's Disease       . For more information concerning pneumonia go to Pneumonia. However, death certificates indicated that Parkinson's Disease was a substantial contributor to the cause of death in only 20% of people with Parkinson's Disease . For 80% of people there were other causes. In order to refer to this article on its own click here.
19th January 2014 - New research
VISUAL DISTURBANCES IN PARKINSON'S DISEASE
Researchers established the prevalence of recurrent visual complaints (RVC) and recurrent visual hallucinations (RVH) in Parkinson's Disease. The most common visual disturbances were found to be : double vision (in 18% of people with Parkinson's Disease), misjudging objects when walking (in 12%), words moving whilst reading (in 17%), and freezing in narrow spaces (in 30%), which was almost exclusively found in people with Parkinson's Disease. The same was true for recurring complex visual hallucinations and illusions, which were found in 17% of people with Parkinson's Disease. Recurring visual complaints were found in 43% of people with Parkinson's Disease. Recurring visual hallucinations were found in 29% of people with Parkinson's Disease. In order to refer to this article on its own click here.
13th January 2014 - New research
PROSAVIN CLINICAL TRIAL RESULTS FOR PARKINSON'S DISEASE
The Lancet, Early Online Publication, 10 January 2014 (S.Palfi, J.M.Gurruchaga, G.S.Ralph, H.Lepetit, et al) Complete abstract
ProSavin uses LentiVector gene delivery technology to deliver genes they suggest are required for the formation of dopamine. The product is administered locally to the relevant region of the brain in order to increase the brain's own capacity for the formation of dopamine. For more information go to Prosavin
A clinical trial assessed the safety and efficacy of ProSavin after bilateral injection into the brains of 15 people who had Parkinson's Disease for more than 5 years. Three doses were assessed : low dose, mid dose and high dose. During the first 12 months 54 drug-related adverse events were reported (51 mild and 3 moderate). The most common adverse events were increased dyskinesias (in 11 out of 15 patients) and on-off phenomena (in 9 out of 15 patients). No serious adverse events related to the study drug or surgical procedure were reported. There was a moderate improvement in Parkinson's Disease symptom scores after 6 months and 12 months. However, in a previous study moderate improvements started declining after only 6 months. In order to refer to this article on its own click here.
12th January 2014 - New book
OXFORD TEXTBOOK OF MOVEMENT DISORDERS
Publisher's description : This volume covers the basic science and clinical concepts underlying movement disorders, as well as the diagnosis and treatment of individual hypokinetic and hyperkinetic movement disorders. Written to aid understanding and treatment of a wide range of movement disorders, it includes a section covering the miscellaneous causes that are routinely encountered by neurologists. It is also supplemented with illustrative video clips that can be accessed through the concurrent online edition. Although firmly rooted in evidence-based management approaches, the authors included their own top tips and experience on the management of difficult cases where no current guidance exists. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
8th January 2014 - New research
THE PREVALENCE OF MUSCULOSKELETAL PROBLEMS IN PARKINSON'S DISEASE
Parkinsonism Related Disorders  19 (7) : 666-669 (Y.E.Kim, W.W.Lee, J.Y.Yun, H.J.Yang, H.J.Kim, B.S. Jeon) Complete abstract
The prevalence of musculoskeletal problems was found to be significantly higher Parkinson's Disease. Around two thirds of people with Parkinson's Disease have them. Only just over a quarter of people with Parkinson's Disease answered that their musculoskeletal problems were recovering. Musculoskeletal problems also tended to receive less treatment when people had Parkinson's Disease.
Common sites of musculoskeletal problems were the lower back, shoulder and knee in that order. The lower back was the site of musculoskeletal problems in nearly half of people with Parkinson's Disease. The shoulder and knee were affected far less often. Among the past diagnoses associated with musculoskeletal problems, frozen shoulder, low back pain, osteoporosis and fracture were more common in people with Parkinson's Disease. Older age, being female, and having a higher score on the Unified Parkinson's Disease Rating Scale were associated with more musculoskeletal problems. For more information go to Musculoskeletal disorders. In order to refer to this article on its own click here.
7th January 2014 - New book
PARKINSON'S DISEASE : IMPROVING PATIENT CARE
Jason S.Hawley, Melissa J.Armstrong, William J.Weiner
Publisher's description : Improving Patient Care is a clinically-focused text for healthcare professionals involved in the everyday management of Parkinson's disease patients. Primary care physicians, general neurologists, medical trainees, and ancillary therapists including mental health professionals, speech therapists, and physical therapists will all find helpful information regarding caring for patients with Parkinson's disease. The 12 chapters cover all aspects of Parkinson's disease care from diagnosis, test selection and early management to handling complications, deciding whether surgical options are appropriate, managing Parkinson's disease patients in the inpatient setting and supporting patients and families during late-stage complications. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
29th December 2013 - New research
L-DOPA PRODRUG FOR PARKINSON'S DISEASE
Movement Disorders  Dec 13 [Epub ahead of print (P.A.Lewitt, F.J.Huff, R.A.Hauser, D.Chen, D.Lissin, K.Zomorodi, K.C.Cundy) Complete abstract
XP21279 is a new L-dopa prodrug being developed by Xenoport for the treatment of Parkinson's Disease. It uses naturally occurring, high capacity nutrient transporters in the gastrointestinal tract to generate active and efficient absorption into the body.
XP21279-carbidopa sustained-release bilayer tablets were developed to provide more continuous exposure to L-dopa. Once absorbed, XP21279 is rapidly converted into L-dopa. In a clinical trial of XP21279, people with Parkinson's Disease were given either XP21279 with carbidopa, or L-dopa with carbidopa, which as Sinemet is the most common means of treating Parkinson's Disease.
The average daily off time was reduced more when using XP21279 but only by 18 minutes. There was little difference between the two in their effect on dyskinesia. However, XP21279 significantly reduced the variability of L-dopa concentration that occurs when using Sinemet (L-dopa and carbidopa). This was achieved by taking XP21279 only three times per day, instead of the four to five times a day that the L-dopa with carbidopa was taken. Therefore, overall, although L-dopa and carbidopa as Sinemet is the most common means of treating Parkinson's Disease, XP21279 was found to be more advantageous. In order to refer to this article on its own click here.
28th December 2013 - New research
FEMALE REPRODUCTIVE FACTORS AND THE RISK OF PARKINSON'S DISEASE
Movement Disorders  Dec 18 [Epub ahead of print] (R.Liu, D.Baird, Y.Park, N.D.Freedman, X.Huang, A.Hollenbeck, A.Blair, H.Chen) Complete abstract
In the largest ever study of its kind, researchers examined female reproductive factors and the risk of Parkinson's Disease. The study involved nearly 120,000 postmenopausal women aged 50 to 71 years. The risk of developing Parkinson's Disease was not significantly associated with female reproductive factors including age at first menstruation, age at first live birth, and age at menopause generally.
However, there was a tendency for an increased risk of Parkinson's Disease in those women who reached menopause when they were 55 or older. Current hormone users for less than 5 years showed a higher risk of developing Parkinson's Disease, which was anywhere between 11% more likely to more than twice as likely. However, this association disappeared for current hormone users after 5 years of use. Oral contraceptive use for ten years was associated with a lower risk of Parkinson's Disease, down to 59% of what would otherwise be expected. In order to refer to this article on its own click here.
20th December 2013 - New review
PESTICIDES ON AIRCRAFT AS A CAUSE OF PARKINSON'S DISEASE
Flight attendants who have developed Parkinson's Disease have taken legal action to try to prove that they have developed Parkinson's Disease because of the insecticides that are routinely sprayed inside aircraft. For more information go to News report and News report
Those pesticides that are known to cause, or be highly associated with Parkinson's Disease are Dieldrin, Rotenone and Organophosphorus pesticides. The fungicides Maneb and Paraquat are also known causes of Parkinson's Disease. Evidence in support of Permathrin, which is used in aircraft, is presently restricted to three animal studies.
Dieldrin levels are above normal in brains of people with Parkinson's Disease. Dieldrin was the most frequently detected Organochlorine pesticide in people with Parkinson's Disease thereby suggesting that dieldrin is associated with Parkinson's Disease. Organophosphorus pesticides are significantly associated with Parkinson's Disease. The frequent use of household pesticides containing Organophosphorus chemicals increased the chances of developing Parkinson's Disease by 71%. Exposure can lead to Parkinsonism. Rotenone can cause the neurochemical, neuropathological and behavioural features of Parkinson's disease, including hypokinesia and rigidity. In order to refer to this article on its own click here.
19th December 2013 - New book
DBS A PATIENT GUIDE TO DEEP BRAIN STIMULATION
Sierra M.Farris, Monique L.Giroux
Publisher's description : DBS A Patient Guide to Deep Brain Stimulation by DBS experts Sierra Farris and Monique Giroux distill a high tech brain surgery into understandable terms for every reader. The authors bring 14 yearsí experience working as a DBS team in treating over 1000 patients. Their easy to read format is packed with practical tips in a patient-centered approach. The authors hope to promote patient empowerment by offering insights that are rarely shared outside the clinic appointment. Filled with case studies, personal stories, practical tips and unique graphics, this book offers in-depth easy to understand explanations for one of the most high tech procedures that can turn back the clock on neurological disease. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
14th December 2013 - News release
ANTIBODIES FOR THE TREATMENT OF PARKINSON'S DISEASE
Roche and Prothena are collaborating to co-develop antibodies for the
treatment of Parkinson's Disease. Prothena's antibody for the
treatment of Parkinson's disease,
PRX002, targets alpha-synuclein. PRX002 is currently in
preclinical development. It is expected to enter Phase 1 clinical trials in
people with Parkinson's Disease in 2014. PRX002 has already been tested in
various cellular and animal models of synuclein-related disease.
10th December 2013 - New book
PARKINSON'S DISEASE TRAPPED - IT'S A GREY MATTER
Christopher C. Evans
Publisher's description : Parkinsonís disease 'Trapped' questions and expands our understanding of Parkinsonís disease. Accessible and meticulously researched, the observations illuminate the grey matter of brain science. It examines three regions of the brain and how these relate to symptoms of Parkinsonís disease, highlighting insights that lead to the discovery of a unique potential cause. Exploring the effects of trauma and lack of blood supply to the brain, it finds missing pieces of the Parkinsonís puzzle. This book explains why people, who smoke cigarettes, drink alcohol, have high cholesterol, and drink too much coffee are less likely to get Parkinson's disease. It presents a controversial three phase model of neurodegeneration. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books
17th November 2013 - New research
FUNGAL CAUSE OF PARKINSON'S DISEASE
Proceedings of the National Academy of Sciences USA  Nov 11 [Epub
ahead of print] (A.A.Inamdar, M.M.Hossain, A.I.Bernstein, G.W.Miller,
Although it has not yet conclusively been proven to have caused Parkinson's Disease in humans, further experiments in human cells revealed that Octenol interfered with two genes involved in the creation of dopamine - the human plasma membrane dopamine transporter (DAT) and the human VMAT ortholog (VMAT2). This demonstrates that 1-octen-3-ol exerts toxicity via disruption of dopamine homeostasis and so may represent a naturally occurring cause of Parkinsonism. Octenol can often be inhaled by humans after being produced in damp, mouldy or water damaged buildings. In order to refer to this article on its own click here.
16th Novemberr 2013- New book
PARKINSON'S DISEASE : A COMPLETE GUIDE FOR PATIENTS AND FAMILIES
William J.Weiner, Lisa M.Shulman, Anthony E.Lang
Publisher's description : Patients and families have long relied on this book for reliable advice about medical, emotional, and physical issues. Bringing this guide up to date, three expert neurologists describe : New understandings gained by five years of additional research on Parkinsonís disease, a new focus on exercise, imaging techniques such as SPECT Scan and DATScan that are aiding in diagnosis, new findings about the genetics, promising uses of new technologies such as tablet devices for people who have trouble communicating, information about impulse control disorders caused by some drugs used to address the symptoms of the disease, A complete update on treatments. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
12th November 2013 - New research
NEW DRUG FOR PARKINSON'S DISEASE PSYCHOSIS
Lancet  Oct 31 [Epub ahead of print] (J.Cummings, S.Isaacson, R.Mills,
H.Williams, K.Chi-Burris, A.Corbett, R.Dhall, C.Ballard)
They took 40mg pimavanserin per day. The primary measure was the antipsychotic benefit using the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD). According to the Parkinson's disease-adapted scale for assessment of positive symptoms (SAPS-PD) those people taking pimavanserin reduced their score by 5.79 compared with a reduction of 2.73 by those taking a placebo. Over 10% of the patients discontinued because of an adverse event. However, in previous clinical trials there was either no effect Complete abstract, or it was beneficial for some but not all measures of psychosis Complete abstract. In order to refer to this article on its own click here.
10th November 2013 - New research
THE PREVALENCE OF HEADACHES IN PARKINSON'S DISEASE
Neurological Sciences  Nov 7 [Epub ahead of print]] Complete abstract
Researchers assessed the prevalence of headache in people with Parkinson's Disease and the association between the side of Parkinon's Disease symptom onset and the side of their headache. Headaches were found to occur significantly less in people with Parkinson's Disease, 40% of whom had headaches, than in people who do not have Parkinson's Disease, 70% of whom had headaches. The prevalence of headaches being significantly lower in people with Parkinon's Disease is unexplained by the researchers.
Fewer people with Parkinson's Disease (74%) had headaches throughout life in contrast to the 94% of people who had headaches throughout life who did not have Parkinson's Disease. Considering only people who had headaches during the previous year, people with Parkinson's Disease had a higher association with migraine rather than tension headaches compared to people who did not have Parkinson's Disease. The headache side in people with Parkinson's Disease was also on the same side as the side of Parkinson's Disease onset in 84 % of people. In order to refer to this article on its own click here.
6th November 2013 - New research
THE CAUSES OF FALLS IN PARKINSON'S DISEASE
Neurologia i neurochirurgia polska  47 (5) : 423-430 (Rudzinska M, Bukowczan S, Stozek J, Zajdel K, Mirek E, Chwala W, Wůjcik-Pedziwiatr M, Banaszkiewicz K, Szczudlik A.) Complete abstract
Neurologia i neurochirurgia polska  47 (5) : 431-437 (Rudzinska M, Bukowczan S, Stozek J, Zajdel K, Mirek E, Chwala W, Wůjcik-Pedziwiatr M, Banaszkiewicz K, Szczudlik A.) Complete abstract
People with Parkinson's Disease suffer falls more frequently than most other people. Over the year falls occurred in 54% of people with Parkinson's Disease. Around 20% of people with Parkinson's Disease fell frequently. This occurred more commonly with age.
Analysis of causes of falls revealed that sudden falls were the most common (31%), followed by episodes of freezing and festination (19%), neurological and sensory disturbances (mostly vertigo) (12%), environmental factors (12%), postural instability (11%), orthostatic hypotension (4%), and severe dyskinesia (3.6%). In people with Parkinson's Disease, factors due to themselves were dominant, whereas in the control group external factors were responsible for falls with the same frequency. Every third fall intensified the fear of walking. Over a third (34%) of falls caused injuries. Among them bruises of body parts other than the head were most frequent. In order to refer to this article on its own click here.
31st October 2013 - News release
SENSORY PEN FOR DETECTING PARKINSON'S DISEASE
A means of diagnosing Parkinsonís Disease is being developed by MANUS Neurodynamica using sensory pen technology. It is called thee DiPAR project. The system, combining sensor and computing technology, requires the patient to perform a set of writing tasks, drawing activities or a combination of both. The system records all movements of the pen as well as other parameters such as drawing pressure, plus acceleration and deceleration of movement, to identify patterns that are indicative of specific kinds of neuromotor disorder. The sensory pen can be used by non-specialists with minimal training so that large numbers of people would be able to be screened.
The systemís software records key features regarding the movement of the pen, relating it to the motion of the limb, particularly the role of the hand and fingers in coordinating overall pen motion. The recordings enable the operator to assess akinesia, bradykinesia, tremor, rigidity and other signs of motor deterioration that cannot be easily detected by other means. The software takes inputs from a variety of sensors in the pen and converts them, using proprietary algorithms, into outcome percentages that represent the likelihood of the presence of Parkinson's Disease or other neuromotor disorders. The method can be viewed in this brief video video of sensory pen technology In order to refer to this article on its own click here.
13th October 2013 - New research
THE LONG TERM EFFECT OF DBS ON PARKINSON'S DISEASE
Journal of the Formosan Medical Association  Oct 5
[Epub ahead of print] (J.L.Jiang,
S.Y.Chen, T.C.Hsieh, C.W.Lee, S.H.Lin, S.T.Tsai)
The aim of this study was to assess the improvements that can be expected after 1 year and after 5 years. Patients with Parkinson's Disease were assessed after 1 year and 5 years according to the Unified Parkinson's disease rating scale (UPDRS) parts I, II, III, and IV scores, the Hoehn and Yahr stage, and Schwab and England activities of daily living (SEADL) scores in the conditions of off-medication/on-stimulation and off-medication/off-stimulation. Further analysis included the changes in the L-dopa equivalent daily dose.
After 1 year significant improvements were seen in the UPDRS parts I, II, III, and IV and the Schwab and England scale. Five years after STN-DBS had been initiated improvements in UPDRS scores were observed only for parts II, III, and IV. In the off-medication/off-stimulation condition no significant improvement was observed. However, after 5 years there were significant deteriorations when compared to the improvements seen after 1 year in the scores for the UPDRS parts I, II, III and the Schwab and England scale.. Therefore, after the improvement experienced after 1 year the long term trend is downwards. For a printable version of this article click here. In order to refer to this article on its own click here.
7th October 2013 - New research
DUAL LAYER L-DOPA CLINICAL TRIAL RESULTS
Parkinsonism Related Disorders  Sep 5 [Epub ahead of print]
(R.Pahwa, K.E.Lyons, R.A.Hauser, S.Fahn, J.Jankovic, E.Pourcher, A.Hsu,
M.O'Connell, S.Kell, S.Gupta)
All three dosages improved Parkinson's Disease, with the 145mg dosage, then the 245mg dosage giving better results. The most commonly reported adverse events with IPX066 included nausea, dizziness, and headache. No unexpected drug-related serious adverse events were reported. For a printable version of this article click here. In order to refer to this article on its own click here.
3rd October 2013 - New research
DEPRESSION TREBLES THE RISK OF PARKINSON'S DISEASE
Neurology  Oct 2 [Epub ahead of print] (Cheng-Che Shen, Shih-Jen
Tsai, Chin-Lin Perng, Benjamin Ing-Tiau Kuo, Albert C.Yang)
Parkinson's Disease is primarily due to the insufficient formation of dopamine in the brain, in the dopaminergic neurons. Besides affecting muscle function and therefore the characteristic muscular symptoms of Parkinson's Disease such as as rigidity and tremor, dopamine insuffiency also affects the emotions.
This is why dopamine insufficiency can also lead to depression. However, even biochemically, dopamine is not the only factor involved in depression, which is why depresssion and Parkinson's Disease do not always coincide. Therefore, depression, even when severe, does not inevitably lead to Parkinson's Disease and why it is possible to have Parkinson's Disease without also having depression.. For a printable version of this article click here. In order to refer to this article on its own click here.
3rd October 2013 - New book
UNDERSTANDING PARKINSON'S DISEASE : AN INTRODUCTION FOR PATIENTS AND CAREGIVERS
Publisher's description : Understanding Parkinsonís Disease offers patients and their caregivers the kind of cutting-edge information that will allow them to successfully confront this debilitating disease on a number of fronts. Patients will also be uniquely exposed to alternative approaches to managing the symptoms of the disease, including allopathic, osteopathic, and naturopathic approaches. The reader will be introduced to essential information on the risk factors associated with Parkinsonís, the signs and symptoms, the different stages of the disease, the various treatments, as well as how the disease develops. Anyone looking for an introduction will find the information they need in this accessible resource. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
29th September 2013 - New research
HOUSEHOLD PESTICIIDES INCREASE THE RISK OF PARKINSON'S DISEASE
International Journal of Epidemiology  Sep 20 [Epub ahead of print]
(S.Narayan, Z.Liew, K.Paul, P.C.Lee, J.S.Sinsheimer, J.M.Bronstein, B.Ritz)
Consequently, researchers investigated whether long term use of household pesticides, especially those containing organophosphorus chemicals, increases the risk of developing or worsening Parkinson's Disease. Frequent use of any household pesticide increased the risk of developing Parkinson's Disease by 47%. Frequent use of products containing organophosphorus chemicals increased the risk of Parkinson's Disease by 71%. Frequent organothiophosphate use almost doubled the risk of Parkinson's Disease. The evidence shows that household use off organophosphoruss pesticides is clearly associated with an increased risk of Parkinson's Disease. For a printable version of this article click here. In order to refer to this article on its own click here.
26th September 2013 - New research
THE WORLD'S LOWEST INCIDENCE OF PARKINSON'S DISEASE
Journal of Neural Transmission  Sep 22 [Epub ahead of print]
(C.L.Ma, L.Su, J.J.Xie, J.X.Long, P.Wu, L.Gu)
The world's lowest incidence of Parkinson's Disease has been found to be in China. Incidence is the rate at which Parkinson's Disease is being newly diagnosed. The incidence of Parkinson's Disease in China, at only 2 people per 100,000 is remarkably low. In constrast, the incidence rate in the U.S.A. is about ten times that number. The prevalence of Parkinson's Disease in China is remarkably high, with 797 per 100,000 being one of the highest rates in the world. The ratio of men to women with Parkinson's Disease is, at 1.29 men for every woman, more typical.
With very high prevalence (those people that have Parkinson's Disease now) and very low incidence (those people that are being diagnosed) means that the number of people in China with Parkinson's Disease must be dropping rapidly, and at a greater rate than anywhere else in the world..The researchers provide no reasons for this. In China, instead of standard Parkinson's Disease drugs, people tend to use more Chinese herbal remedies, a number of which are known to have effect in Parkinson's Disease. For more information go too Herbal Medicines for Parkinson's Disease For a printable version of this article click here. In order to refer to this article on its own click here.
The former Chinese leader Chairman Mao is known to have had Parkinson's Disease. However, it is never disclosed in China that Chairman Mao, who is given almost God like status in China, ever actually had Parkinson's Disease.
22nd September 2013 - New research
THE EFFECT OF TEN YEARS WITH PARKINSON'S DISEASE
Parkinsonism Related Disorders  18 supplement, 3 : S10-S14 28 (3) :
380-383 (A.Hassan, S.S.Wu, P.Schmidt, I.A.Malaty, Y.F.Dai, J.M.Miyasaki,
They had an average of two additional medical disorders with arthritis (49%) and heart problems (32%) being the most common. Most of them (87%) took at least 2 medications, with L-dopa (96%), dopamine agonists (45%) and antidepressants (37%) being the most common. Most of them were not currently utilizing physical, occupational or speech therapy, but two-thirds of them reported engaging in physical activity. Deep brain stimulation was documented in 22%. Overall the mean health-related quality of life and caregiver burden was impaired in all domains. For a printable version of this article click here. In order to refer to this article on its own click here.
21st September 2013 - New research
COFFEE INTAKE AND THE RISK OF DYSKINESIA
Movement Disorders  28 (3) : 380-383 (A.M.Wills, S.Eberly, M.Tennis,
A.E.Lang, S.Messing, D.Togasaki, C.M.Tanner, C.Kamp, J.F.Chen, D.Oakes,
Researchers examined the association between the intake of caffeine and the time taken to develop dyskinesia. Those people who consumed 12 ounces of coffee per day, which is about two cups, reduced their likelihood of developing dyskinesia to 61%. Those people who consumed 4 to 12 ounces of coffee per day, which is less than two cups per day, reduced their likelihood of developing dyskinesia to 73%. The authors suggest tha these results support the possibility that caffeine may reduce the likelihood of developing dyskinesia. For a printable version of this articlee click here. In order to refer to this article on its own click here.
16th September 2013 - News report
BILLY CONNOLLY DIAGNOSED WITH PARKINSON'S DISEASE
The 70 year old Scottish comedian Billy Connolly has been diagnosed with Parkinson's Disease but has vowed to continue with his stage and screen career despite also having prostate cancer. Besides being known for stand up comedy on television and in large arenas he has appeared as a comedian and as a serious actor in films such as The Last Samurai, The Hobbit, Indecent Proposal, Muppet Treasure Island, and Gulliver's Travels. For more information go to Billy Connolly. Connollyís spokesman revealed that "Billy has been assured by experts that the findings will in no way inhibit or affect his ability to work, and he will start filming a TV series as well as undertaking an extensive theatrical tour." For more details go to Daily Mail.
9th September 2013 - New review
FUTURE FORMS OF L-DOPA FOR PARKINSON'S DISEASE
The forms of L-dopa presently being developed are likely to completely change the way that L-dopa is used. They include Inhaled L-dopa, Dual layer L-dopa, Subcutaneous L-dopa, L-dopa prodrug, Melevodopa and AcuForm.
Mucuna Pruriens has been a source of L-dopa since ancient times. As a drug, L-dopa started out as a treatment on its own. Sinemet and Madopar combined L-Dopa with a decarboxylase inhibitor in order to reduce the loss of L-dopa before it was used. In order to spread out the effect of L-dopa, controlled release versions of Sinemet and Madopar were then produced, Stalevo added Entacapone to that combination. Entacapone is a COMT inhibitor, which is able to slow down the degradation of L-dopa. An improved version of Stalevo called ODM-101 is already being developed. Parcopa is an orally disintegrating combination of L-dopa and carbidopa, which is the same combination as Sinemet. Duodopa is a combination of L-dopa and carbidopa in the form of a gel, which is administered throughout the day using a portable pump directly into the small intestine through a surgically placed tube.
New forms of L-dopa presently being developed for the treatment of Parkinson's Disease are :
AcuForm in combination with L-dopa and carbidopa (DM-1992) makes use of the properties of polymers that help to deliver L-dopa over a longer period of time. For more information go to Acuform
6th September 2013 - New research
SAFINAMIDE CLINICAL TRIAL RESULTS
European Journal of Neurology  September 11 [Epub ahead of print]
(A.H.Schapira, F.Stocchi, R.Borgohain, M.Onofrj, M.Bhatt, P.Lorenzana,
V.Lucini, R.Giuliani, R.Anand)
In a one year clinical trial people with Parkinson's Disease received 100mg or 200mg Safinamide daily. They were assessed according to how long it was before they had to increase their dopamine agonist dose or add another Parkinson's Disease treatment. People receiving 100 mg/day safinamide experienced a significantly lower rate of intervention compared with placebo, of 25% instead of 51% and a small delay before the need to increase other Parkinson's Disease treatments of 9 days.
In a previous study of once daily dosages of 50mg to 100mg Safinamide improved Parkinson's Disease symptoms after six months and reduced "off" time when added on to the use of existing Parkinson's Disease treatments. However, the reduction in "off" time in comparison to the use of a placebo was minimal. The increase in "on" time beyond that of a placebo was only 40 minutes for 50mg safinamide, and 50 minutes for 100mg safinamide. For more information go to the Complete abstract. For a printable version of this article click here. In order to refer to this article on its own click here.
4th September 2013 - New book
DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA
Publisher's description : In Dementia with Lewy Bodies and Parkinson's Disease Dementia, Dr. J. Eric Ahlskog draws on 30 years of clinical and research work at Mayo Clinic to arm patients and families with crucial information that will enable them to work in tandem with their doctors. Dr. Ahlskog clearly explains all aspects of these disorders, their causes, symptoms, most effective drug treatments, proper doses, and which medications to avoid. He also discusses the complications that can arise in treating these conditions, given the variety of available medications and their possible side effects and interactions. Dr. Ahlskog shows that optimal medical treatment can markedly improve the quality of life for both patients and family. Click here for more details. For more books concerning Parkinson's Disease go to Parkinson's Disease Books.
1st September 2013 - New research
NEUPRO CLINICAL TRIAL RESULTSS
PLoS One  8 (7) : e69738 (C.Q.Zhou, S.S.Li, Z.M.Chen, F.Q.Li, P.Lei,
|GO TO AUGUST 2013|
ARCHIVESJuly August September October November December March April May June July August September October November December March April May June July August September October November December